Total Parenteral Nutrition-induced Cholestasis
10
0
0
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
20.0%
2 terminated out of 10 trials
50.0%
-36.5% vs benchmark
10%
1 trials in Phase 3/4
150%
3 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Compassionate Use of Omegaven IV Fat Emulsion
Compassionate Use of Omegaven in Children
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Compassionate Use of Omegaven IV Fat Emulsion
Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition